Identify microRNAs in Cachexia in Pancreatic Carcinoma

Last updated: February 7, 2025
Sponsor: University of Oklahoma
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Treatment

Pancreatic cancer microRNA and messenger RNA expression.

Clinical Study ID

NCT05275075
OU-SCC-MIRPANCA
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female patient, who is ≥ 18 years old at the time of informed consent.

  2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior toconsent with clinical discretion or pathology confirmed as adenocarcinoma.

  3. Patient has stage I or higher disease who is considered a candidate for surgicalresection of pancreatic cancer, with or without neoadjuvant chemotherapy.

  4. Ability to provide written informed consent and HIPAA authorization.

Exclusion

Exclusion Criteria:

  1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgicalresection.

  2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Pancreatic cancer microRNA and messenger RNA expression.
Phase:
Study Start date:
December 07, 2022
Estimated Completion Date:
May 01, 2029

Study Description

This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.

Connect with a study center

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma 73117
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.